Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): L19TNF
Therapeutic Area: Oncology Product Name: Fibromun
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
The findings of the study show how Philogen’s proprietary antibody-cytokine fusions, called immunocytokines, demonstrated striking single-agent anti-cancer activity in immunocompetent preclinical models bearing orthotopic glioblastoma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Temferon
Therapeutic Area: Oncology Product Name: Temferon
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
Unlike antigen-restricted Chimeric Antigen Receptor T cells (CAR-T), Temferon™ is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, which remains one of the main unresolved challenge in Immuno oncology.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MEN1611,Cetuximab
Therapeutic Area: Oncology Product Name: MEN1611
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2020
Details:
The new study, called C-PRECISE-01, will evaluate MEN1611 and cetuximab in patients with PIK3CA mutated, RAS and RAF wild-type metastatic colorectal cancer (mCRC), failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
